β-Interleukin II (44-56)
(Synonyms: H2N-Ile-Leu-Asn-Gly-Ile-Asn-Asn-Tyr-Lys-Asn-Pro-Lys-Leu-OH ) 目录号 : GP10080Cytokine,regulating WBC
Cas No.:309247-07-2
Sample solution is provided at 25 µL, 10mM.
β-Interleukin II (44-56), (C68H113N19O19) is a peptide with the sequence NH2-ILE-LEU-ASN-GLY-ILE-ASN-ASN-TYR-LYS-ASN-PRO-LYS-LEU-COOH, MW= 1500.7. Interleukin 2 (IL-2) belongs to the interleukin family, a type of cytokine signaling molecule in the immune system, and it is a protein that regulates the activities of the white blood cells (leukocytes, often lymphocytes) responsible for immunity. IL-2, a soluble hormone-like mediator of the immune system, was the first interleukin molecule to be identified and characterized. It is necessary for the growth, proliferation, and differentiation of T cells to become 'effector' T cells. IL-2 is normally produced by T cells during an immune response and is necessary for the development of T cell immunologic memory, which depends upon the expansion of the number and function of antigen-selected T cell clones.IL-2 is also necessary for the maturation of a subset of T cells, termed regulatory T cells, during T cell development in the thymus.
References:
1. Cantrell DA, Smith KA (June 1984). "The interleukin-2 T-cell system: a new cell growth model". Science 224 (4655): 1312–6.
2. Smith KA (May 1988). "Interleukin-2: inception, impact, and implications". Science 240 (4856): 1169–76.
3. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (August 1995). "Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases". J. Immunol. 155 (3): 1151–64.
4. ThorntonAM, Shevach EM (July 1998). "CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production". J. Exp. Med. 188 (2): 287–96.
Cas No. | 309247-07-2 | SDF | |
别名 | H2N-Ile-Leu-Asn-Gly-Ile-Asn-Asn-Tyr-Lys-Asn-Pro-Lys-Leu-OH | ||
Canonical SMILES | C[C@@H](CC)[C@H](N)C(N[C@H](CC(C)C)C(N[C@H](CC(N)=O)C(NCC(N[C@H]([C@@H](CC)C)C(N[C@H](CC(N)=O)C(N[C@H](CC(N)=O)C(N[C@H](CC1=CC=C(O)C=C1)C(N[C@H](CCCCN)C(N[C@H](CC(N)=O)C(N2CCC[C@H]2C(N[C@H](CCCCN)C(N[C@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O | ||
分子式 | C68H113N19O19 | 分子量 | 1500.74 |
溶解度 | ≥ 150mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.6663 mL | 3.3317 mL | 6.6634 mL |
5 mM | 0.1333 mL | 0.6663 mL | 1.3327 mL |
10 mM | 0.0666 mL | 0.3332 mL | 0.6663 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet